Personal tools
You are here: Home NCI Could Fund Some Challenge Grants That Miss NIH Funding, Director Says
Navigation
Subscribe or renew subscription
Google Ad Links
 
Document Actions

NCI Could Fund Some Challenge Grants That Miss NIH Funding, Director Says

From The Cancer Letter, June 26, 2009:

Cancer-related Challenge Grants that aren’t selected for stimulus funding by the NIH Director’s Office will get another shot at stimulus funding by NCI, Institute Director John Niederhuber said earlier this week.

NIH plans to use $200 million of the stimulus funds to support 200 of these grants at $1 million each over two years. If those numbers don’t change, the funding success rate would be one percent. NCI could use some of its $1.257 billion in stimulus funding to support Challenge Grants that don’t make the NIH cutoff, Niederhuber said.

“We will look at those and make choices about which ones will be funded using resources assigned to NCI,” he said in remarks to the NCI Board of Scientific Advisors June 22.

For further information on NCI's plans for use of stimulus funding, click on The Cancer Letter Archive at left to read the June 26 issue (subscription or day pass required). _____
tags:
Friday, June 26, 2009 in NCIresearch funding  | Permalink |  Comments (0)
del.icio.us   Digg   Yahoo   Google   Spurl
Log in


Forgot your password?
Top Headlines
« July 2010 »
Su Mo Tu We Th Fr Sa
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31
2010-07-02 00:00
00:00-00:00 Three Cooperative Groups To Combine Statistical Center Operations
2010-07-09 00:00
00:00-00:00 In Exit Interview, Niederhuber Says Clinical Trials System Must Refocus To Emphasize Translational Studies
2010-07-15 00:00
00:00-00:00 Harold Varmus Takes NCI Helm With No Promises, No Clichés
00:00-00:00 Prominent Duke Scientist Claimed Prizes He Didn't Win, Including Rhodes Scholarship
2010-07-23 00:00
12:00-12:00 Note to Cancer Letter Subscribers for Friday, July 23
14:40-14:40 The Potti Scandal: Biostatisticians Send Letter to Varmus, Lancet Oncology Expresses Concern
Categories:
FDA (16)
Medicare (4)
NCI (43)
cancer prevention (4)
cancer screening (19)
cancer treatment (16)
drug development (33)
legislation (6)
news makers (3)
oncology profession (12)
policy issues (31)
research funding (41)
Google Ads
 

Powered by Plone CMS, the Open Source Content Management System

This site conforms to the following standards: